Reversing breast cancer bone metastasis by metal organic framework-capped nanotherapeutics via suppressing osteoclastogenesis. (June 2022)

• Record Type: Journal Article
• Authors: Zou, Binhua; Xiong, Zushuang; He, Lizhen; Chen, Tianfeng
• Is Part Of: Biomaterials. Volume 285(2022)
• Publication Date: 2022-06
• Subjects: Malignant bone tumor -- Osteoclast -- PTT -- Chemo-photothermal therapy -- Nanoparticles; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2022.121549
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Bone metastasis is the major cause of cancer-related morbidity and mortality. To avoid further osteolysis, current treatment ideas focus on tumor cell and the inhibition of osteoclast. Herein, zeolitic imidazolate framework-8–capped Cu2-X Se composite nanoplatform (ICG@Cu2-X Se-ZIF-8) is developed for chemodynamic therapy (CDT) and photothermal therapy (PTT) treatment of malignant breast cancer bone tumors. The rational design of ZIF-8 encapsulation greatly reduces the accumulation of Cu2-X Se to damage the normal cells. Under acidic microenvironment in tumor, ZIF-8 is cleaved to release Cu2-X Se, which can subsequently degrade into Cu (+) and Cu (2+) ions to initiate a Fenton-like reaction inducing CDT. Meanwhile, Cu2-X Se is used to be an effective photothermal transduction agent for exerting the PTT effect. What's more, the selenium element in Cu2-X Se can regulates selenoprotein to inhibit tumor cells and osteoclasts. Of note, the hyperthermia induced by PTT can further enhance the CDT effect in tumor, achieving a synergistic PTT/CDT effect. Based on these advantages, ICG@Cu2-X Se-ZIF-8 effectively suppresses the tumor cells in bone tissue, and reduces the erosion of bone tissue via suppressing osteoclastogenesis. In conclusion, this study demonstrates the potential action mechanism of ZIF-8–capped nanomedicine against osteolysis in bone metastasis.